Advertisement

Topics

Ocugen, Inc. Receives FDA Orphan Drug Designation For OCU300 (Brimonidine Tartrate) For The Treatment Of Ocular Graft Versus Host Disease

20:00 EDT 8 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Ocugen, Inc. Receives FDA Orphan Drug Designation For OCU300 (Brimonidine Tartrate) For The Treatment Of Ocular Graft Versus Host Disease

NEXT ARTICLE

More From BioPortfolio on "Ocugen, Inc. Receives FDA Orphan Drug Designation For OCU300 (Brimonidine Tartrate) For The Treatment Of Ocular Graft Versus Host Disease"

Quick Search
Advertisement